A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)

Recruiting

DAPAgliflozinA Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)

Sponsor:

University of Michigan

Code:

NCT06785116

Conditions

Gestational Hypertension

Hypertension in Pregnancy

Pre-Eclampsia

Superimposed Pre-Eclampsia

Cardiovascular Complication

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Placebo

Dapagliflozin 10mg Tab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-21. This information was provided to ClinicalTrials.gov by University of Michigan on 2025-03-11.